Drug Profile

Research programme: Parkinson's disease therapeutic lentivirus - American Gene Technologies

Alternative Names: AG PD 001; AG-PD - Parkinson's disease therapeutic lentivirus

Latest Information Update: 28 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator American Gene Technologies International
Developer American Gene Technologies International; Johns Hopkins University
Class Gene therapies
Mechanism of Action Poly(ADP-ribose) polymerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Sep 2025 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Parenteral)
13 Mar 2018 American Gene Technologies International has patent protection for its lentiviral vector technology in USA
01 Aug 2016 Preclinical trials in Parkinson's disease in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com